Expression of androgen receptor in breast cancer and its significance as a prognostic factor

Annals of Oncology

Volumn 22, Issue 6, 2011, Pages 1288-1294

  Yu, Q ^a,b   Niu, Y ^a   Liu, N ^a   Zhang, J Z ^c   Liu, T J ^a   Zhang, R J ^a   Wang, S L ^a   Ding, X M ^a   Xiao, X Q ^a  

^a TIANJIN MEDICAL UNIVERSITY   (China)

^b Jinghai Hospital   (China)

^c 306 HOSPITAL OF PLA   (China)

Author keywords

Androgen receptor; Basal like subgroup; Biological characteristics; Breast cancer; clinicopathological characteristics; Ductal carcinoma in situ

Indexed keywords

ANDROGEN RECEPTOR; ESTROGEN RECEPTOR; PROGESTERONE RECEPTOR;

ARTICLE; BREAST CANCER; CANCER CLASSIFICATION; CANCER INVASION; CHINESE; CONTROLLED STUDY; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; INTRADUCTAL CARCINOMA; INVASIVE DUCTAL BREAST CARCINOMA; MAJOR CLINICAL STUDY; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION;

EID: 79957865877     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdq586     Document Type: Article

References (33)

1. Shidham VB, Komorowski RA, Machhi JK. Androgen receptor expression in metastatic adenocarcinoma in females favors a breast primary. Diagn Pathol 2006; 1: 34.
2. Gonzalez LO, Corte MD, Vazquez J, et al. Androgen receptor expression in breast cancer: relationship with clinicopathological characteristics of the tumors, prognosis, and expression of metalloproteases and their inhibitors. BMC Cancer 2008; 8: 149.
3. Riva C, Dainese E, Caprara G, et al. Immunohistochemical study of androgen receptors in breast carcinoma. Evidence of their frequent expression in lobular carcinoma. Virchows Arch 2005; 447: 695-700.
4. Nahleh Z. Androgen receptor as a target for the treatment of hormone receptornegative breast cancer: an unchartered territory. Future Oncol 2008; 4: 15-21.
5. Agoff SN, Swanson PE, Linden H, et al. Androgen receptor expression in estrogen receptor-negative breast cancer. Immunohistochemical, clinical, and prognostic associations. Am J Clin Pathol 2003; 120: 725-731.
6. Lea OA, Kvinnsland S, Thorsen T. Improved measurement of androgen receptors in human breast cancer. Cancer Res 1989; 49: 7162-7167.
7. Agrawal AK, Jeleń M, Grzebieniak Z, et al. Androgen receptors as a prognostic and predictive factor in breast cancer. Folia Histochem Cytobiol 2008; 46: 269-276.
8. Nicolas Diaz-Chico B, German Rodriguez F, Gonzalez A, et al. Androgens and androgen receptors in breast cancer. J Steroid Biochem Mol Biol 2007; 105: 1-15.
9. Peters AA, Buchanan G, Ricciardelli C, et al. Androgen receptor inhibits estrogen receptor-alpha activity and is prognostic in breast cancer. Cancer Res 2009; 69: 6131-6140.
10. Doane AS, Danso M, Lal P, et al. An estrogen receptor-negative breast cancer subset characterized by a hormonally regulated transcriptional program and response to androgen. Oncogene 2006; 25: 3994-4008.
11. Sørlie T, Tibshirani R, Parker J, et al. Repeated observation of breast tumor subtypes in independent gene expression data sets. Proc Natl Acad Sci USA 2003; 100: 8418-8423.
12. Rakha EA, El-Rehim DA, Paish C, et al. Basal phenotype identifies a poor prognostic subgroup of breast cancer of clinical importance. Eur J Cancer 2006; 42: 3149-3156.
13. Tang P, Skinner KA, Hicks DG. Molecular classification of breast carcinomas by immunohistochemical analysis: are we ready? Diagn Mol Pathol 2009; 18: 125-132.
14. Harvey JM, Clark GM, Osborne CK, Allred DC. Estrogen receptor status by immunohistochemistry is superior to the ligand-binding assay for predicting response to adjuvant endocrine therapy in breast cancer. J Clin Oncol 1999; 17: 1474-1481.
15. Nielsen TO, Hsu FD, Jensen K, et al. Immunohistochemical and clinical characterization of the basal-like subtype of invasive breast carcinoma. Clin Cancer Res 2004; 10: 5367-5374.
16. Rakha EA, El-Sayed ME, Green AR, et al. Prognostic markers in triple-negative breast cancer. Cancer 2007; 109: 25-32.
17. Carey LA, Perou CM, Livasy CA, et al. Race, breast cancer subtypes, and survival in the Carolina Breast Cancer Study. JAMA 2006; 295: 2492-2502.
18. Kuroda H, Ishida F, Nakai M, et al. Basal cytokeratin expression in relation to biological factors in breast cancer. Hum Pathol 2008; 39: 1744-1750.
19. Evans R. The steroid and thyroid hormone receptor super family. Science 1988; 240: 889-895.
20. Perou CM, Sørlie T, Eisen MB, et al. Molecular portraits of human breast tumours. Nature 2000; 406: 747-752.
21. Sorlie T, Wang Y, Xiao C, et al. Distinct molecular mechanisms underlying clinically relevant subtypes of breast cancer: gene expression analyses across three different platforms. BMC Genomics 2006; 7: 127.
22. Cheang MC, Voduc D, Bajdik C, et al. Basal-like breast cancer defined by five biomarkers has superior prognostic value than triple-negative phenotype. Clin Cancer Res 2008; 14: 1368-1376.
23. Bidard FC, Conforti R, Boulet T, et al. Does triple-negative phenotype accurately identify basal-like tumour? An immunohistochemical analysis based on 143 'triple-negative' breast cancers. Ann Oncol 2007; 18: 1285-1286.
24. Shibuya R, Suzuki T, Miki Y, et al. Intratumoral concentration of sex steroids and expression of sex steroid-producing enzymes in ductal carcinoma in situ of human breast. Endocr Relat Cancer 2008; 15: 113-124.
25. Duffy MJ, Maguire TM, Hill A, et al. Metalloproteinases: role in breast carcinogenesis, invasion and metastasis. Breast Cancer Res 2000; 2: 252-257.
26. Köhrmann A, Kammerer U, Kapp M, et al. Expression of matrix metalloproteinases (MMPs) in primary human breast cancer and breast cancer cell lines: new findings and review of the literature. BMC Cancer 2009; 9: 188.
27. Boddy JL, Fox SB, Han C, et al. The androgen receptor is significantly associated with vascular endothelial growth factor and hypoxia sensing via hypoxia-inducible factors HIF-1a, HIF-2a, and the prolyl hydroxylases in human prostate cancer. Clin Cancer Res 2005; 11: 7658-7663.
28. Zhong H, Semenza GL, Simons JW, et al. Up-regulation of hypoxia-inducible factor 1alpha is an early event in prostate carcinogenesis. Cancer Detect Prev 2004; 28: 88-93.
29. Bos R, Zhong H, Hanrahan CF, et al. Levels of hypoxia-inducible factor-1 alpha during breast carcinogenesis. J Natl Cancer Inst 2001; 93: 309-314.
30. Gonzalez LO, Corte MD, Junquera S, et al. Expression of androgen receptor and two androgen-induced proteins (apolipoprotein D and pepsinogen C) in ductal carcinoma in situ of the breast. Histopathology 2007; 50: 866-874.
31. Koo JS, Jung W, Jeong J. The Predictive Role of E-cadherin and androgen receptor on in vitro chemosensitivity in triple-negative breast cancer. Jpn J Clin Oncol 2009; 39: 560-568.
32. Toth-Fejel S, Cheek J, Calhoun K, et al. Estrogen and androgen receptors as comediators of breast cancer cell proliferation: providing a new therapeutic tool. Arch Surg 2004; 139: 50-54.
33. Traina TA, Wolff AC, Giri D, et al. Androgen receptor inhibition for the treatment of AR+/ER-/PR-metastatic breast cancer. Breast Cancer Symposium, San Francisco, CA, October 8-10, 2009 (Abstr 251).